Building on the evolution of the past 18 years, Genesis 2019 will assemble senior executives and decision-makers from across the Life Science, Healthcare and Technology field to present, discuss and demonstrate their collective insight and thought leadership for the sector, themselves and their stakeholders. The meeting will be held on December 11th at the QEII Centre, Westminter, London, UK.

Dirk Beher will share his experience at the Meeting Biotech Rising Star panel, on December 11th at 2:00 pm (Rutherford Room, 4th floor).

Anglonordic is the only life science conference in the UK that is exclusively for European investors and R&D companies from the Nordics and the UK to connect with each other. The 16th annual conference will be held on May 9th, 2019 at County Hall in London, UK. 

Our CEO Dirk Beher will take part in the panel discussion “Technologies and treatments – What’s on the horizon?” scheduled at 1:30 PM.

The 24th International partnering conference BIO-Europe will be held on November 5th-7th, 2018 at the Bella Center in Copenhagen, Denmark. The event is expected to draw over 4,000 industry attendees for three days of high level networking, representing more than 2,000 companies from over 60 countries. BIO-Europe attracts a wide range of business leaders, including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors and other industry experts.

Our CEO Dirk Beher will take part to the panel discussion “The current climate of CNS R&D: Lessons learned and new research” on Monday, November 5th from 5:15 pm to 6:15 pm, at Bio-Europe (Room  C2). The panel will cover the current climate of CNS R&D, specifically lessons learned from past failures and new research to advance the treatment of neurological disorders. CNS disorders are expected to make up 14.7 percent of the global disease burden by 2020, representing the largest burden of any disease group, according to the US National Institute of Mental Health. Despite decades of research and billions in investments, this sector has posed significant challenges and setbacks. However, ambitious novel research and new breakthroughs are changing the landscape. Experts in this field will highlight what is being done differently now and discuss the future of CNS in biopharma.